Atirmociclib not checked

Pfizer · PF-07220060 · Cohort 5

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
8 active
15 in total · 6 in the EU
Targets
 

What this is

How it works
Blocks CDK enzymes that let cells divide, to slow the growth of cancer cells.-ciclib: cyclin-dependent kinase inhibitors WHO name stem
How it’s given
“Atirmociclib tablet given orally twice daily, plus giredestrant capsule given orally once per day”In the company’s words, NCT07890597 on ClinicalTrials.gov
Tested for
Breast Cancer (2 trials), Advanced or Metastatic Breast Cancer (2 trials), Advanced Breast Cancer (2 trials), Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-), Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer and 7 more
Main trialPhase 3
“The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior…”In the company’s words, NCT06760637 on ClinicalTrials.gov
Other names
PF-07220060 · Cohort 5 · Fed · Cohort 6 · Fasted PPI · Cohort 7 · Fed PPI · Cohort 8 · third tablet formulation

Other drugs for Breast Cancer

All 397 drugs for Breast Cancer

Coming up6

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials15

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 2 Jan 2029 Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Phase 3Not yet recruiting 13 Apr 2032 A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
Phase 2Active, not recruiting 12 Jan 2026 A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Phase 2Recruiting 27 Aug 2029 Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Phase 2Recruiting 7 Oct 2029 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Phase 1/2Active, not recruiting 5 Sep 2025 A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Phase 1Recruiting 14 Aug 2027 A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
Phase 1Not yet recruiting 22 Mar 2030 A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
Phase 2Completed 10 Jul 2025 A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
Phase 1Completed 12 Apr 2024 A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults
Phase 1Completed 23 Jun 2024 A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults
Phase 1Completed 11 May 2025 A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060
Phase 1Completed 26 Oct 2025 A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants
Phase 1Completed 24 Nov 2025 A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
Phase 1Completed 21 Jul 2026 Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Atirmociclib

Following is part of Solo: you see every change to Atirmociclib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in